The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase

Clinical Biochemistry

Volumn 40, Issue 1-2, 2007, Pages 1-5

  Kassai, Andrea ^c   Illyés, László ^a   Mirdamadi, Hossein Z ^c   Seres, Ildiko ^c   Kalmár, Tímea ^c   Audikovszky, Mária ^b   Paragh, György ^c  

^a Szent Ferenc Hospital   (Hungary)

^b Szent Imre Hospital   (Hungary)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Atorvastatin; Cholesteryl ester transfer protein (CETP); High density lipoprotein (HDL); Lecithin:cholesterol acyltransferase (LCAT); Paraoxonase (PON)

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; LIPID COMPOSITION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SAMPLE SIZE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; APOLIPOPROTEINS; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL ESTER TRANSFER PROTEINS; FEMALE; HEPTANOIC ACIDS; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; PYRROLES;

EID: 33845797118     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2006.05.016     Document Type: Article

References (28)

1. Barter P. CETP and atherosclerosis. Arterioscler Thromb Vasc Biol 20 (2000) 2029-2031
2. Glomset J.A., Assmann G., Gjone E., and Norum K.R. Lecithin:cholesterol acyltransferase deficiency and fish-eye disease. In: Scriver C.R., Beaudent A.L., Sly W.S., and Valle D. (Eds). The metabolic basis of inherited diseases (1995), McGraw-Hill, New York, NY 1933-1952
3. Kuivenhoven J.A., Stalenhoef A.F.H., Hill J.S., et al. Two novel molecular defects in the LCAT gene are associated with fish eye disease. Arterioscler Thromb Vasc Biol 16 (1996) 294-303
4. Navab M., Berliner J.A., Watson A.D., et al. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Dis 16 (1996) 831-842
5. Mackness M.I., Arrol S., Abbott C., and Durrington P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104 (1993) 129-135
6. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., and La Du B.N. Paraoxonase inhibits high density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101 (1998) 1581-1590
7. Steinberg D., Parthasarathy S., Carew T.E., et al. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320 (1989) 915-924
8. Witztum J.L., and Steinberg D. Role of oxidized low-density lipoprotein in atherogenesis. J Clin Invest 88 (1991) 1785-1792
9. Illingworth D.R., and Tolbert J.A. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther 16 (1994) 336-385
10. Nawrocki J.W., Weiss S.R., Davidson M.H., Sprecher D.L., et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 15 (1995) 678-682
11. Jones P., Kafonek S., Laurora I., and Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81 (1998) 582-587
12. Mohammadi A., Macri J., Newton R., Romain T., et al. Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells. Arterioscler Thromb Vasc Biol 18 (1998) 783-793
13. Guerin M., Lassel T.S., Le Goff W., Farnier M., et al. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 20 (2000) 189-197
14. Illingworth D.R., Crouse III J.R., Hunninghake D.B., et al., Simvastatin Atorvastatin HDL Study Group. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin 17 (2001) 43-50
15. Harangi M., Seres I., Varga Z.s., et al. Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage. Eur J Clin Pharm 60 (2004) 685-691
16. Frick M.H., Elo O., Haapa K., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317 (1987) 1237-1245
17. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989) 8-15
18. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 (1999) 410-418
19. Rubins H.B., Robins S.J., Collins D., et al. Distribution of lipids in 8500 men with coronary artery disease. [Department of Veterans Affairs HDL Intervention Trial Study Group]. Am J Cardiol 75 (1995) 1196-1201
20. Athyros V.G., Papageorgiou A.A., Mercouris B.R., et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus "usual" care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 18 (2002) 215-219
21. Guerin M., Egger P., Soudant C., et al. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis 163 (2002) 287-296
22. Fuhrman B., Koren L., Volkova N., Keidar S., Hayek T., and Aviram M. Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis 164 (2002) 179-185
23. Le N.-A., Innis-Whitehouse W., Li X., Bakker-Arkema R., Black D., and Brown W.V. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin. Metabolism 49 (2000) 167-177
24. Mishra M., Durrington P., Mackness M., et al. The effect of atorvastatin on serum lipoproteins in acromegaly. Clin Endocrinol (Oxf) 62 (2005) 650-655
25. Rye K.-A., Clay M.A., and Barter P.J. Remodelling of high density lipoproteins by plasma factors. Atherosclerosis 145 (1999) 227-238
26. Hoeg J.M., Santamarina-Fojo S., Berard A.M., et al. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci U S A 93 (1996) 11448-11453
27. Agellon L.B., Walsh A., Hayek T., et al. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J Biol Chem 266 (1991) 10796-10801
28. Paragh G., Torocsik D., Seres I., et al. Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia. Curr Med Res Opin 20 (2004) 1321-1327